Processing...
Clinical Trials for Melanoma
Search
Search
There are 161 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
161 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults (≥18) with locally advanced or metastatic solid tumors that are refractory/intolerant to standard therapies or lack standard options (ECOG 0–2; no active CNS/leptomeningeal metastases) receive IV JMT108 every 2 weeks (with possible alternate schedules in expansion). JMT108 is a fully human anti–PD-1 antibody fused to IL-15 intended to combine checkpoint blockade with IL-15–driven activation/proliferation of CD8+ T cells and NK cells, with tumor-specific expansion cohorts including lung, colorectal, hepatocellular, gastric cancers, melanoma, and other solid tumors.
ClinicalTrials.gov ID: NCT07317505
TrialFetch AI summary: Adults with measurable metastatic uveal melanoma (ECOG 0–2), including heavily pretreated patients (HLA-A*02:01–positive patients generally expected to have received prior tebentafusp when available), are treated with NBM-BMX, an oral HDAC8-selective histone deacetylase inhibitor aimed at epigenetic modulation to promote tumor cell-cycle arrest and apoptosis. NBM-BMX is given as empty-stomach oral capsules twice daily in continuous 28-day cycles with dose escalation (100–400 mg BID) followed by expansion until progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT07136181
TrialFetch AI summary: Adults with unresectable or metastatic melanoma that has progressed after at least one prior systemic therapy including anti–PD-1 (ECOG 0–1; treated/stable brain metastases allowed) receive DOC1021 (dubodencel), a personalized autologous dendritic-cell vaccine made from mobilized peripheral blood cells and loaded with patient-specific tumor antigens (tumor lysate + amplified tumor mRNA) to induce Th1/cytotoxic T-cell responses, with peginterferon alfa-2a as an immune adjuvant. Treatment includes filgrastim mobilization with leukapheresis, two image-guided perinodal DOC1021 injections 2 weeks apart with 4 weeks of weekly peginterferon (optional 6‑month booster with additional peginterferon), and anti–PD-1 is held until ~6 weeks after the first DOC1021 dose (may be resumed later per protocol).
ClinicalTrials.gov ID: NCT07288112
TrialFetch AI summary: Adults with metastatic or unresectable locally advanced NSCLC, esophageal squamous cell carcinoma, or cutaneous melanoma after standard therapy or 1–2 prior systemic regimens receive IV PF-08046033 in 21-day cycles. PF-08046033 is an investigational GPNMB-directed antibody-drug conjugate delivering auristatin S to GPNMB-expressing tumor cells, with dose escalation followed by tumor-specific expansion cohorts.
ClinicalTrials.gov ID: NCT07519655
TrialFetch AI summary: Adults with advanced measurable solid tumors who have exhausted or are ineligible for standard therapies, with a melanoma-focused expansion requiring known BRAF status and generally ≤3 prior systemic lines. All patients receive BI 3810944 monotherapy, an investigational small-molecule anticancer agent with undisclosed target/mechanism, given initially weekly then typically every 3 weeks.
ClinicalTrials.gov ID: NCT07224425
TrialFetch AI summary: Adults with refractory unresectable or metastatic solid tumors and an accessible injectable lesion, with expansion cohorts in cutaneous squamous-cell carcinoma, melanoma, head and neck squamous-cell carcinoma, NSCLC, and triple-negative breast cancer. Patients receive intratumoral N17350 every 2 weeks, a recombinant mutant porcine pancreatic elastase targeting the neutrophil elastase/ELANE pathway and designed to induce immunogenic tumor-cell death.
ClinicalTrials.gov ID: NCT07339176
TrialFetch AI summary: Adults with ECOG 0–1 and measurable, unresectable stage III/IV NRAS-mutant melanoma or other advanced solid tumors refractory to, intolerant of, or declining standard therapy receive oral RLY-8161, a selective NRAS inhibitor designed to suppress RAS–MAPK signaling while sparing KRAS and HRAS. Dose escalation is followed by expansion at the selected recommended dose(s).
ClinicalTrials.gov ID: NCT07584226
TrialFetch AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.
ClinicalTrials.gov ID: NCT04787042
TrialFetch AI summary: This trial enrolls adults with unresectable or metastatic melanoma or advanced non-small-cell lung cancer who have progressed after at least anti-PD-1/PD-L1 therapy, using an autologous tumor-infiltrating lymphocyte product (IOV-4001) genetically edited to knock out PD-1 via TALEN technology, administered after lymphodepleting chemotherapy and followed by high-dose IL-2. PD-1 knockout aims to enhance TIL antitumor activity by reducing exhaustion.
ClinicalTrials.gov ID: NCT05361174
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors or diffuse large B-cell lymphoma who have exhausted standard therapies, evaluating the investigational oral CBL-B inhibitor NX-1607 (which enhances antitumor immunity by blocking a negative regulator of immune cell activation) as monotherapy or in combination with paclitaxel. Eligible tumor types include ovarian, gastric, head and neck, melanoma, NSCLC, prostate, mesothelioma, triple-negative breast, urothelial, cervical, microsatellite-stable colorectal cancer, and DLBCL/Richter transformation.
ClinicalTrials.gov ID: NCT05107674